Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Elevations in serum creatinine concentration: concerning or reassuring?

Benjamin J Epstein1

  • 1Department of Pharmacy and Research, North Florida/South Georgia Veterans Health-System, Gainesville, Florida 32608, USA. benjamin.epstein@med.va.gov

Pharmacotherapy
|May 28, 2004
PubMed
Summary

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improve vascular health but are underused due to renal function concerns. Early, temporary drops in glomerular filtration rate (GFR) are expected and linked to better long-term kidney outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SGLT-2 inhibitors and their potential in the treatment of diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy·2013
Same author

Management of hypertension with fixed-dose triple-combination treatments.

Therapeutic advances in cardiovascular disease·2013
Same author

The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond.

Expert review of cardiovascular therapy·2012
Same author

Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.

Pharmacotherapy·2012
Same author

Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study).

Journal of clinical hypertension (Greenwich, Conn.)·2011
Same author

Less RAAS is more, or not.

Expert review of cardiovascular therapy·2011

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) significantly reduce morbidity and mortality in vascular disease.
  • Despite proven benefits, the utilization of ACE inhibitors and ARBs remains suboptimal due to concerns about renal function.
  • Clinicians often hesitate to prescribe these vital medications owing to potential short-term decreases in glomerular filtration rate (GFR).

Discussion:

  • The transient decrease in GFR observed after initiating ACE inhibitors or ARBs is a functional response, not indicative of pathology.
  • This physiological change is directly related to the renin-angiotensin system's role in maintaining GFR.
  • Misinterpretation of this early GFR change as an adverse effect leads to unnecessary withholding of beneficial therapies.

Related Experiment Videos

Key Insights:

  • Early elevations in serum creatinine, often accompanying a GFR decrease, are paradoxically associated with improved long-term renal outcomes.
  • This finding supports the continued use of ACE inhibitors and ARBs, even when initial renal function changes occur.
  • Understanding the physiological basis of these changes is crucial for appropriate clinical management.

Outlook:

  • Increased clinician awareness of the expected physiological response to renin-angiotensin system blockade can improve ACE inhibitor and ARB utilization.
  • Further education on the renoprotective effects and interpretation of early renal function changes will optimize patient care.
  • This understanding can help overcome barriers to prescribing these essential medications, ultimately benefiting patients with vascular disease and renal insufficiency.